Login / Signup

Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia.

Pau MontesinosChristian RecherSusana VivesEwa ZarzyckaJianxiang WangGiambattista BertaniMichael HeuserRodrigo do Tocantins CaladoAndre C SchuhSu-Peng YehScott R DaigleJianan HuiShuchi S PandyaDiego A GianolioStephane de BottonHartmut Döhner
Published in: The New England journal of medicine (2022)
Ivosidenib and azacitidine showed significant clinical benefit as compared with placebo and azacitidine in this difficult-to-treat population. Febrile neutropenia and infections were less frequent in the ivosidenib-and-azacitidine group than in the placebo-and-azacitidine group, whereas neutropenia and bleeding were more frequent in the ivosidenib-and-azacitidine group. (Funded by Agios Pharmaceuticals and Servier Pharmaceuticals; AGILE ClinicalTrials.gov number, NCT03173248.).
Keyphrases
  • acute myeloid leukemia
  • allogeneic hematopoietic stem cell transplantation
  • clinical trial
  • double blind
  • low grade
  • acute lymphoblastic leukemia
  • study protocol
  • high grade
  • placebo controlled